OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Freedland on Standardized PSA Testing in Prostate Cancer

March 6th 2020

Stephen J. Freedland, MD, discusses the importance of standardizing prostate-specific antigen testing in prostate cancer.

Dr. Connolly on Potential Benefit of Postmastectomy Radiation for Breast Cancer

March 5th 2020

Eileen Connolly, MD, PhD, discusses the possible benefit of postmastectomy radiation for patients with breast cancer.

Dr. Ritchie on Immunological Recovery With Venetoclax and Ibrutinib in MCL

March 5th 2020

David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.

Dr. Grossbard on the Utility of PI3K Inhibitors in Follicular Lymphoma

March 5th 2020

Michael L. Grossbard, MD, discusses the utility of PI3K inhibitors in follicular lymphoma.

Dr. Raje on the Efficacy of Belantamab Mafodotin in Multiple Myeloma

March 5th 2020

Noopur Raje, MD, discusses the utility of belantamab mafodotin in the treatment of patients with multiple myeloma.

Dr. McDermott on VEGF/PD-1 Inhibition in RCC

March 5th 2020

David F. McDermott, MD, discusses the research behind combining VEGF inhibitors with PD-1/PD-L1 inhibitors in renal cell carcinoma treatment.

Dr. Charlton on the Emergence of Biomarkers in HCC

March 5th 2020

Michael R. Charlton, MD, MBBS, discusses the emergence of biomarkers in hepatocellular carcinoma.

Dr. Saint Fleur-Lominy on Impact of Ruxolitinib on Symptom Burden in MPNs

March 5th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the effects ruxolitinib has on symptom burden in patients with myeloproliferative neoplasms.

Dr. Armstrong on the Utility of Liquid Biopsies in mCRPC

March 5th 2020

Andrew J. Armstrong, MD, discusses the utility of liquid biopsies in metastatic castration-resistant prostate cancer.

Dr. Emens on Immune-Related Adverse Events in Ovarian Cancer

March 4th 2020

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

Dr. Choi on Frontline Treatment Considerations in CLL

March 4th 2020

Michael Choi, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Dr. Goldman on the Impact of Liquid Biopsies in Lung Cancer

March 4th 2020

Jonathan W. Goldman, discusses the impact of liquid biopsies in lung cancer.

Dr. O'Donnell on Unanswered Questions in Multiple Myeloma

March 4th 2020

Betsy O’Donnell, MD, discusses unanswered questions in multiple myeloma.

Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian Cancer

March 4th 2020

Lori Brisbin, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.

Dr. Khan on Retrospective Analysis of Demographics in CRC and Gastric Cancer

March 4th 2020

Amir Khan, MD, discusses a large retrospective database analysis on colorectal cancer and gastric cancer presented at the 2020 Gastrointestinal Cancers Symposium.

Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast Cancer

March 4th 2020

Sara M. Tolaney, MD, MPH, discusses novel approaches in treating patients with HER2-positive breast cancer.

Dr. Pagel on Time-Limited Therapy in CLL

March 4th 2020

John M. Pagel, MD, PhD, discusses time-limited therapy in chronic lymphocytic leukemia.

Dr. Mirhadi on Patient Populations of Lung Cancer Optimal for Radiation

March 4th 2020

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

Dr. Lee on Treatment Options mRCC

March 4th 2020

Chung-Han Lee, MD, PhD, discusses treatment options for patients with metastatic renal cell carcinoma.

Dr. Katz on Preoperative Chemotherapy in Resectable Pancreatic Cancer

March 4th 2020

Matthew H.G. Katz, MD, FACS, discusses the utility of preoperative chemotherapy for patients with resectable pancreatic cancer.